SCHEMBL1339348

SCHEMBL1339348

Cn1c(=O)c(-c2ccc(Cl)cc2Cl)cc2c3cc(-c4csc(CNS(C)(=O)=O)n4)ccc3n(C)c21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 1/20 0.43
▸ CNR1 P21554 7/20 0.38
▸ GABRA1 P14867 2/20 0.38
▸ ADRA2C P18825 2/20 0.38
▸ SLC6A3 Q01959 2/20 0.38
▸ ADRB3 P13945 1/20 0.38
▸ ADRA2B P18089 1/20 0.38
▸ HTR2A P28223 1/20 0.38
▸ HTR2C P28335 1/20 0.38
▸ OPRD1 P41143 1/20 0.38
▸ EGFR P00533 3/20 0.36
▸ SLC2A1 P11166 1/20 0.34
▸ RIPK2 O43353 1/20 0.34
▸ NOD2 Q9HC29 1/20 0.34
▸ ABL1 P00519 1/20 0.34
▸ EIF4E P06730 1/20 0.34
▸ CNR2 P34972 6/20 0.34
▸ HPSE Q9Y251 1/20 0.33
▸ TRPA1 O75762 3/20 0.33
▸ ALOX5 P09917 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1339436 0.87 EIF4E (0.38) CNR1GABRA1ADRA2CSLC6A3EGFR
SCHEMBL1339047 0.87 EIF4E (0.37) CNR1GABRA1ADRA2CSLC6A3EGFR
SCHEMBL1338822 0.87 PARP1 (0.37) PARP1CNR1GABRA1ADRA2CSLC6A3
SCHEMBL1339161 0.87 EIF4E (0.39) CNR1GABRA1ADRA2CSLC6A3ADRB3
SCHEMBL1338539 0.85 L3MBTL1 (0.37) CNR1EIF4ECNR2HPSEKDM4E
SCHEMBL1339432 0.84 CNR1 (0.40) PARP1CNR1GABRA1ADRA2CSLC6A3
SCHEMBL1337288 0.84 GABRA1 (0.41) CNR1GABRA1EIF4ECNR2HPSE
SCHEMBL4716844 0.84 EIF4E (0.37) CNR1GABRA1ADRA2CSLC6A3EGFR
SCHEMBL1337140 0.83 CNR1 (0.36) CNR1GABRA1ADRA2CSLC6A3EGFR
SCHEMBL1336976 0.83 TRIM24 (0.41) PARP1CNR1GABRA1ADRA2CSLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 PARP1 370/4885CNR1 262/4885GABRA1 1457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback